AGIBOT Completes Over 100-Million-Yuan Series A Financing, Accelerating the New Chapter of Intelligent Surgery

In July 2024, AGIBOT Medical Technology (Suzhou) Co., Ltd. (AGIBOT) completed the signing of a series A financing of over 100 million yuan. This round of financing was led by Cenova Capital, followed by HGC, and received additional investment from existing shareholders Oriza Seed, Sherpa Healthcare Partners, and Suzhou Yihe. The funds from this round of financing will be used to accelerate the company’s innovative R&D, mass production delivery, and commercialization.

Prior to this, AGIBOT has completed seed, angel and Pre-A rounds of financing, with a total amount of more than RMB 100 million yuan, and the investors are all professional investment institutions and investors who have long been focusing on the healthcare field.

Investors in This Round:

Cenova Capital

Founded in 2010, Cenova Capital is one of the earliest professional funds in China to engage in investments in the medical and health and life-science fields. It is committed to promoting the transformation, upgrading, and innovation of China’s medical industry. Currently, Cenova Capital manages seven healthcare industry funds. The fund contributors are well-known international and domestic institutional investors, including Asian sovereign wealth funds, government agencies, domestic and foreign insurance and financial institutions, and multinational enterprises.

HGC

Established in 2017, HGC is based on the four major industries of Hengdian Group: electrical and electronic, medical and health, film and television, culture, and tourism, and modern services. It focuses on technological changes. With a professional team, it studies the upstream and downstream of the industrial chain, enabling the commercial application of innovative technologies through its mature industrial foundation. HGC collaborates with major scientific research institutions, incubators, industrial parks, investment institutions, and government departments, integrating international resources to build a complete investment chain from VC, PE to mergers and acquisitions, creating a comprehensive investment ecosystem. It provides a high-quality growth environment for projects and builds an excellent ecological platform.

Oriza Seed

Oriza Seed is a market-oriented and professional early-stage equity investment platform under Oriza Holdings. It focuses on investment opportunities in start-up and early-growth-stage entrepreneurial enterprises in the two major fields of technology and healthcare. The total fund size exceeds 7 billion yuan, including both VC funds and regional-targeted angel funds. Since its establishment in 2013, Oriza Seed has had an investment style that emphasizes the early-stage, prefers technology, and adheres to its promises. It enjoys a good reputation among technology-based early-stage start-up enterprises. So far, it has invested in nearly 300 enterprises, aiming to inject growth impetus into start-up enterprises and grow together with entrepreneurs.

Sherpa Healthcare Partners

Sherpa Healthcare Partners is a fund management company specializing in early-stage and growth-stage investments in the medical and health field. Adhering to the concept of “investing early, in innovation, and accurately”, based on long-term accumulated industry insights and superior resources, it constructs an investment portfolio around the unmet rigid clinical needs in major disease areas, covering areas such as gene technology and applications, biopharmaceuticals, medical device diagnostics, and digital healthcare. It expands along the industrial depth and across the upstream and downstream to form enterprise synergy, with investment layouts in both China and the United States. The Sherpa team has both industrial and investment backgrounds. By actively sharing operation and management experience with partners and providing a forward-looking perspective on the entire industrial chain, it supports enterprises in making key decisions at critical development stages, helping them achieve growth in business performance and enterprise value. Through a decade of dedication, long-term professional focus, and learning accumulation, Sherpa Investment has established its brand and built a comprehensive ability system covering project sourcing, post-investment value-added services, and exits. Upholding the value of “Investing in Health, Achieving Others to Achieve Oneself”, the Sherpa team is honored to work with numerous outstanding entrepreneurs, bringing benefits to human health through innovative technologies and products, participating in and witnessing the growth of China’s medical industry, and striving to be the most reliable partner for entrepreneurs climbing the peak of life science.

Suzhou Yihe

Founded in 2012, Suzhou Yihe focuses on the medical and healthcare sector, investing in high-quality medical and healthcare enterprises led by innovative technologies, especially those with high-precision technologies and industry-leading R&D and innovation, while helping the industry to achieve a number of high-quality and internationally competitive medical enterprises.